STATEN ISLAND, N.Y., August 14, 2026
Acurx Pharmaceuticals, Inc. reported its second-quarter 2026 financial results and provided a business update highlighting continued progress for ibezapolstat (IBZ), its lead antibiotic candidate being developed for Clostridioides difficile infection (CDI) and recurrent CDI. The company said its development program is advancing toward international Phase 3 clinical trials, while recent regulatory discussions with the U.S. Food and Drug Administration (FDA) provided guidance on the potential use of a single Phase 3 study as a pivotal trial supporting a future New Drug Application. Acurx also reported encouraging research suggesting that its DNA polymerase IIIC inhibitors may preserve the gut microbiome while maintaining antibacterial activity. The company ended the quarter with $10.7 million in cash, compared with $7.6 million at December 31, 2025.
Ibezapolstat Advances in CDI and Recurrent CDI
Ibezapolstat is an orally administered antibiotic designed as a Gram-positive selective-spectrum antibacterial that targets bacterial DNA polymerase IIIC, an enzyme required for DNA replication. Acurx is preparing ibezapolstat for international Phase 3 development in acute CDI while also advancing a clinical program focused on multiply recurrent CDI. The company’s approach is intended to provide activity against C. difficile while preserving beneficial components of the intestinal microbiome. In July, research presented at the Anaerobe Society of the Americas Congress indicated that beneficial gut microorganisms may have an opportunity to repopulate following ibezapolstat treatment, potentially supporting efforts to reduce recurrence. Experimental data also showed ibezapolstat activity against C. difficile biofilms. The company has previously received FDA and EMA agreement regarding key elements of its pivotal Phase 3 CDI program, including study design, patient population, endpoints and registration safety requirements.
Regulatory and Research Progress Strengthens Pipeline
Acurx reported several developments supporting the broader DNA polymerase IIIC inhibitor platform. In July, the company’s research and development team met with the FDA to seek guidance regarding its plan for a single Phase 3 study and its potential acceptability as a pivotal trial for NDA submission. The company also continued its scientific collaboration with Leiden University Medical Center to investigate DNA polymerase IIIC inhibition and develop novel antibacterial agents targeting resistant Gram-positive pathogens. Research activities include efforts to generate a three-dimensional structure of Staphylococcus aureus polymerase C in complex with an Acurx inhibitor, potentially supporting future drug discovery against MRSA. In August, Acurx received FDA Conditional Acceptance and USPTO Trademark Allowance for its proprietary name for ibezapolstat. New patents granted in Japan and Mexico further expanded the company’s intellectual property portfolio, which now includes six U.S. patents and ten additional international patents covering important aspects of ibezapolstat and the ACX-375C program.
Advertisement
Acurx Reports $10.7 Million Cash Position
For the second quarter ended June 30, 2026, Acurx reported $10.7 million in cash, supported by approximately $2.5 million in gross proceeds from a registered direct offering and $0.8 million raised through its Equity Line of Credit during the quarter. Research and development expenses increased to $1.1 million, compared with $0.5 million in the second quarter of 2025, primarily due to higher manufacturing and consulting costs associated with the recurrent CDI program. General and administrative expenses declined to $1.2 million from $1.7 million, reflecting lower professional, legal and share-based compensation expenses. The company reported a net loss of $2.3 million, or $0.53 per diluted share, compared with a $2.2 million loss, or $1.89 per diluted share, in the prior-year quarter. With ibezapolstat positioned for Phase 3 development and the recurrent CDI program progressing, Acurx Pharmaceuticals is focused on securing the resources needed to advance its lead antibiotic while expanding its pipeline of targeted therapies against difficult-to-treat Gram-positive bacterial infections.
Source:Capricor Therapeutics,, press relese
